Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Completed · Phase 2

Conditions studied: Mantle Cell Lymphoma

In brief

The primary objective of this study was to evaluate the efficacy of ibrutinib in participants with relapsed or refractory MCL. The secondary objective was to evaluate the safety of a fixed daily dosing regimen (560 mg daily) of PCI-32765 in this population.

Key facts

Study ID

NCT01236391

Run by

Pharmacyclics LLC.

People needed

115

Starts

2011-02-01

Expected to finish

2014-01-01

Last updated by the study team

2015-08-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women ≥ 18 years of age
• ECOG performance status of ≤ 2
• Pathologically confirmed MCL, with documentation of either overexpression of cyclin D1 or t(11;14), and measurable disease on cross sectional imaging that is ≥ 2 cm in the longest diameter and measurable in 2 perpendicular dimensions
• Documented failure to achieve at least partial response (PR) with, or documented disease progression disease after, the most recent treatment regimen
• At least 1, but no more than 5, prior treatment regimens for MCL (Note: Subjects having received ≥2 cycles of prior treatment with bortezomib, either as a single agent or as part of a combination therapy regimen, will be considered to be bortezomib-exposed.)
• Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty
• Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local subject privacy regulations)
• Major exclusion criteria:
• Prior chemotherapy within 3 weeks, nitrosoureas within 6 weeks, therapeutic anticancer antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation therapy within 3 weeks, or major surgery within 2 weeks of first dose of study drug
• Any life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of PCI-32765 capsules, or put the study outcomes at undue risk
• Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification
• Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
• Any of the following laboratory abnormalities:
• Absolute neutrophil count (ANC) < 750 cells/mm3 (0.75 x 109/L) unless there is documented bone marrow involvement
• Platelet count < 50,000 cells/mm3 (50 x 109/L) independent of transfusion support unless there is documented bone marrow involvement
• Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) ≥ 3.0 x upper limit of normal (ULN)
• Creatinine > 2.0 x ULN

Where it is running

• Stanford University School of Medicine — Stanford, California, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Cll Research and Treatment Program — New Hyde Park, New York, United States
• New York Presbyterian Hospital/Cornell Medical Center — New York, New York, United States
• The Ohio Sate university — Columbus, Ohio, United States
• Oregon Health & Science University — Portland, Oregon, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• University of Virginia School of Medicine Hospital — Charlottesville, Virginia, United States
• University of Wisconsin — Madison, Wisconsin, United States
• Klinikum der Universitat Munchen - Campus Grosshadern — München, Germany
• Universitatsklinikum Ulm, Klinik fur Innere Medizin II — Ulm, Germany
• Oddzail Kliniczny Onkologil — Bydgoszcz, Poland
• Malopolskie Centrum Medyczne — Krakow, Poland
• MTZ Clinical Research Sp. z o.o. — Warsaw, Poland
• Centre for Experimental Cancer Medicine — London, United Kingdom
• Christie Hospital — Manchester, United Kingdom
• Derriford Hospital — Plymouth, United Kingdom
• Southampton General Hospital — Southampton, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.